SCHEMBL14497511

SCHEMBL14497511

CC(=O)c1cnccc1CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.43
▸ SIRT3 Q9NTG7 1/20 0.43
▸ HASPIN Q8TF76 1/20 0.39
▸ PKM P14618 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ KDM4C Q9H3R0 4/20 0.37
▸ KDM6B O15054 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KDM4A O75164 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4D Q6B0I6 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3818724 0.86 TDP1 (0.44) TDP1SIRT3HASPINROCK2ROCK1
SCHEMBL3880004 0.82 KDM4C (0.50) TDP1SIRT3KDM4CKDM6BKDM4E
SCHEMBL4734614 0.81 CYP2E1 (0.43) TDP1SIRT3HASPINPKMROCK2
SCHEMBL18599002 0.79 KDM6B (0.43) TDP1SIRT3PKMKDM4CKDM6B
SCHEMBL7256409 0.79 SIRT3 (0.39) TDP1SIRT3HASPINROCK2ROCK1
SCHEMBL28317597 0.77 TDP1 (0.50) TDP1SIRT3HASPINROCK2ROCK1
SCHEMBL15906582 0.76 TSHR (0.39) TDP1SIRT3CYP11B1CYP11B2KDM4C
SCHEMBL15763685 0.75 TDP1 (0.36) TDP1SIRT3HASPINROCK2ROCK1
SCHEMBL11236770 0.74 KDM4C (0.44) TDP1SIRT3HASPINKDM4CKDM6B
SCHEMBL844847 0.74 CYP2E1 (0.43) HASPINCYP11B1CYP11B2L3MBTL1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR TDP1 327/4885SIRT3 1597/4885HASPIN 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback